CELU Valuation Metrics
FCF$-13.25M
FCF Growth Rate—
EPS Growth (CAGR)—
WACC10.00%
Celularity Inc - Class A
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Did you know?
CELU's revenue grew at a 3.9% CAGR over the last 6 years.
Current Price
$0.98
+2.83%Profile
Valuation (TTM)
Market Cap$27.88M
P/E-0.30
EV—
P/B—
Shares Out28.33M
P/Sales1.05
Revenue$26.55M
EV/EBITDA—
Celularity Inc - Class A (CELU) Valuation
Fair Value Models
Graham Number, PEG-based, and Earnings-based models
View Fair Value →CELU Valuation & Fair Value Analysis
Celularity Inc - Class A (CELU) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The price-to-earnings (P/E) ratio is -0.30. Price-to-sales ratio is 1.05. PEG ratio is -0.01.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Celularity Inc - Class A's intrinsic value.